Medtronic Expands Continuous Glucose Monitoring (CGM) Solutions for People with Diabetes Using Insulin Injections with CE Mar...
July 19 2016 - 9:00AM
New
Guardian(TM) Connect
System Will Be Launched in Q2 FY17 Outside the U.S.
DUBLIN - July 19, 2016 -
Medtronic plc (NYSE:MDT), the global leader in medical technology,
today announced it has received CE (Conformité Européenne) Mark for
its new Guardian(TM) Connect
mobile continuous glucose monitoring (CGM) system for people with
diabetes using insulin injection therapy. Guardian Connect is the
first smartphone-enabled CGM system from Medtronic to receive CE
Mark and further demonstrates the company's intent to provide
solutions for people across the diabetes care continuum. The system
will be launched on a country-by-country basis in the second
quarter of fiscal year 2017, beginning with select countries in
Europe, Asia Pacific, and Latin America.
With Guardian Connect, people on insulin
injections will be able to check their current glucose level
anytime on their mobile device, as easily as checking other
information sources such as email, the weather or social media.
They can also be alerted of high and low glucose levels on their
mobile device, helping them confidently avoid or address high and
low glucose situations. Guardian Connect is the first and only
mobile CGM system with customizable SMS text alerts enabling care
partners to receive high and low glucose alerts on any connected
mobile device. The system also features the option to automatically
upload the data daily into CareLink(TM) therapy
management software, which reduces the burden of data upload for
both people on insulin injection therapy as well as their
healthcare providers.
"Having continuous, real-time access to glucose
values and being alerted to important trends and events is key for
people with diabetes. With our new Guardian Connect system, we've
continued to innovate so we can deliver these insights for people
with diabetes on insulin injection therapy," said Annette Brüls,
president, Diabetes Service and Solutions at Medtronic. "Guardian
Connect is also compatible with our CareLink®
diabetes therapy management platform and arms healthcare providers,
their patients and care partners with actionable data to help
improve day-to-day diabetes management and make long-term therapy
adjustments. Expanding our solutions to help more people with
diabetes no matter where they are on the care continuum is central
to our goal of transforming diabetes care for greater freedom and
better health."
The Guardian Connect system consists of a small
wearable CGM device that takes glucose readings every five minutes
(288 times a day) and sends these glucose values directly to a
smartphone app. People on insulin injection therapy can use the
system to check glucose levels on their mobile phones, enabling
them to see highs and lows in real-time, understand the trends and
help improve their daily management of diabetes. Alerts can also be
set up if glucose levels go above or below preset levels, helping
patients prevent or address potentially dangerous high and low
glucose events. All of this information can be shared with care
partners via SMS text messages and via access to the real-time CGM
tracing from any web-enabled device. In addition, healthcare
providers can leverage automatic daily data uploads via
CareLink.
The Guardian Connect smartphone app will initially
be available with iOS devices. Medtronic is currently developing an
Android version of the Guardian Connect app for release at a later
date. The Guardian Connect system is not yet available for sale in
the United States.
The Guardian(TM) Connect mobile
continuous glucose monitoring (CGM) system for people with diabetes
using insulin injection therapy is the first smartphone-enabled CGM
system from Medtronic to receive CE Mark and further demonstrates
the company's intent to provide solutions for people across the
diabetes care continuum.
Click the thumbnail above for a larger
image.
About Continuous Glucose
Monitoring (CGM)
A CGM system provides continuous, real-time trend information about
glucose levels for people with diabetes. It allows for appropriate
intervention (after verifying with a blood fingerstick test) to
mitigate hyperglycemia (high blood sugar) or hypoglycemia (low
blood sugar), maximizing the patient's time in the optimal glucose
target range. To use a CGM system, the person with diabetes inserts
a tiny sensor beneath the skin, typically in the abdomen. The
sensor, which measures glucose levels from the fluid under the
skin, is attached to a transmitter that sends readings to a
wearable monitor or the insulin pump every five minutes. Alerts and
alarms can be customized to notify patients up to 30 minutes before
they reach personal preset low or high sensor glucose limits. CGM
provides a more complete picture because it reveals high and low
glucose levels that periodic blood fingerstick testing might
miss.
About the Diabetes Group at
Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change
the way people manage diabetes. The company aims to transform
diabetes care by expanding access, integrating care and improving
outcomes, so people living with diabetes can enjoy greater freedom
and better health.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 85,000 people worldwide, serving physicians,
hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to
take healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
Contacts:
Amanda Sheldon
Public Relations
+1-818-576-4826
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
HUG#2029277
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024